271 related articles for article (PubMed ID: 30141348)
21. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
22. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
Desai A; Small EJ
Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
[TBL] [Abstract][Full Text] [Related]
26. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
Naoun N; Vano YA
Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
[No Abstract] [Full Text] [Related]
27. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
28. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
29. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
30. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
[No Abstract] [Full Text] [Related]
32. Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?
Bersanelli M; Buti S
Acta Biomed; 2016 Sep; 87(2):224-5. PubMed ID: 27649009
[TBL] [Abstract][Full Text] [Related]
33. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
34. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
35. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
36. Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Ciccarese C; Iacovelli R; Mosillo C; Tortora G
Clin Genitourin Cancer; 2018 Oct; 16(5):e1069-e1071. PubMed ID: 30005936
[No Abstract] [Full Text] [Related]
37. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
38. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib and nivolumab for renal cell carcinoma.
Worley L
Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]